Ainsleigh Stone Associate

Ainsleigh is an associate in the intellectual property team, advising on the protection and exploitation of a full range of intellectual property rights. She has a particular interest in the life sciences and technology sectors.
  • Profile
  • Services
  • Sectors
Ainsleigh began her legal career in New Zealand where she advised a diverse range of organisations in the technology, luxury goods and media sectors on a wide array of contentious and non-contentious intellectual property matters.

Ainsleigh's background in pharmacology also means she has a particular interest in the R&D and commercialisation path of pharmaceuticals and other medical technologies. Her recent highlights include advising a clinical-stage AI pharmaceutical development company on an out-licensing arrangement for the treatment of atopic dermatitis and advising on the investment of a spin-out company specialising in the development of polymer nanomedicines.
  • Intellectual Property
Exploitation of intellectual property
Advising clients in relation to the generation of value from their intellectual property, including through negotiating agreements to secure appropriate rights and the creation of revenue streams via licensing and collaboration arrangements.

Due diligence of intellectual property
Advises on the intellectual property aspects of corporate transactions, including mergers and acquisitions.

Confidential Information
Advising clients in relation to the protection of confidential information, including trade secrets.

Brand strategy, protection, and enforcement
Providing advice on brand protection including clearance searches and developing multi-jurisdictional filing strategies.

View services: Intellectual property
  • Life Sciences
Advising BenevolentAI on a strategic collaboration with Merck to identify and develop novel drug candidates in the fields of oncology, neurology, and immunology.

Advising a European biopharmaceutical company on the licensing of patented biologics for the potential treatment of hypophosphatasia and other rare bone disorders.

Advising on the intellectual property aspects of an investment into a spin-out polymer nanomedicine development company. Key to the transaction was the renegotiation of one of the company's key patent licence agreements to align with the company's revised business model.

Advising a European CDMO on a potential co-development, co-commercialisation and licensing arrangement relating to an anaesthetic product.

View services: Life Sciences
© Stephenson Harwood LLP 2016. Any reference to Stephenson Harwood in this document means Stephenson Harwood LLP and/or its affiliated undertakings. Any reference to a partner is used to refer to a member of Stephenson Harwood LLP.